Companies: 10,795·Total market cap: $144.5T
Virax Biolabs Group Limited

Virax Biolabs Group Limited

VRAXNASDAQHealthcare● Active
$0.19
$-0.02(-9.87%)
Market Cap$817156
P/E Ratio—
52W High$1.14
52W Low$0.1
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Virax Biolabs Group Limited (VRAX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001885827 · VRAX · NASDAQ · as of Jun 9, 2026

Filing snapshot

141
Total Filings
6-K
Latest Form
2026-05-26
Most Recent
2022
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001885827 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2025-07-02
Fiscal Year End
Jul 2, 2025
Accession No.
0000950170-25-093260
Primary Document
vrax-20250331.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001885827 · Accession 0000950170-25-093260

Latest Key Filings

6-KQuarterly Report
6-K
2026-05-26
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-22
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-14
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-10
View
3Initial Statement of Beneficial Ownership
3
2026-03-31
View
3Initial Statement of Beneficial Ownership
3
2026-03-20
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-03-18
View
3Initial Statement of Beneficial Ownership
3
2026-03-18
View
3Initial Statement of Beneficial Ownership
3
2026-03-18
View
3Initial Statement of Beneficial Ownership
3
2026-03-18
View
3Initial Statement of Beneficial Ownership
3
2026-03-18
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-17
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-01-30
View
424B3424B3
424B3
2025-12-31
View
Showing 1–15 of 141 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001885827  |  Exchange: NASDAQ · Healthcare

Virax Biolabs Group Limited (NASDAQ: VRAX) has submitted 141 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2022. As a Healthcare sector company with CIK 0001885827, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Virax Biolabs Group Limited's most comprehensive regulatory disclosure. The most recent Virax Biolabs Group Limited 10-K was filed on 2025-07-02 for fiscal year ending 2025. Historical VRAX 10-K annual reports are available from 2021 through 2025.

Investors researching Virax Biolabs Group Limited SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
NKGN SEC Filings →MLEC SEC Filings →GTBP SEC Filings →ARTL SEC Filings →ELAB SEC Filings →NCEL SEC Filings →ATXI SEC Filings →DRMA SEC Filings →
→ VRAX Financials→ VRAX Earnings→ VRAX Insider Trades

Frequently Asked Questions

VRAX SEC Filings · 8 questions

Virax Biolabs Group Limited (VRAX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 141 filings and access original documents at no cost. Virax Biolabs Group Limited's CIK is 0001885827.

VRAX SEC filingsVirax Biolabs Group Limited SEC documentsfind VRAX 10-K